BUZZ-BCAL Diagnostics hits 9-month high on ethics approval in Australia
Reuters
Dec 03, 2025
BUZZ-BCAL Diagnostics hits 9-month high on ethics approval in Australia
** BCAL Diagnostics BDX.AX jumps as much as 9.1% to A$0.12, highest since February 24
** Diagnostics firm gets national ethics approval in Australia for a registry study on up to 24,000 women where subjects will use co's breast cancer screening product BREASTESTplus as part of their clinical treatment
** CEO says registry will accelerate doctor adoption while collecting real-world data to support future reimbursement
** YTD, BDX gains 13.4%
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.